Izilendustat is a potent inhibitor of prolyl hydroxylase which can stabilize hypoxia inducible factor- 1 alpha (HIF- lα) and hypoxia inducible factor-2 (HIF-2). Izilendustat has the potential for researching diseases that relate to the body’s inmmune response like colitis and other inflammatory bowel diseases (extracted from patent WO2011057115A1 and WO2011057121A1)[1][1].
[1]. Joseph H, et al. Prolyl hydroxylase inhibitors. Patent WO2011057115A1. [2]. Joseph H, et al. Compositions and methods for treating colitis. Patent WO2011057121A1.